Verdezyne Inc has reported that it has “… been awarded a $1.7 million grant from the National
Institute of Allergy And Infectious Diseases (NIAID) for a period of 1.5 years. The goal of this program is to quickly and reliably advance the construction of directed mutant gene libraries widely considered important technology tools for synthetic biology.”
More from a Release dated October 19:
Verdezyne Receives Federal Grant to Advance Synthetic Biology Tools | Business Wire
CARLSBAD, Calif.–(BUSINESS WIRE)–Verdezyne,
Inc., a privately-held synthetic biology company developing
fermentation processes for industrial chemicals and biofuels, announced
today that they have been awarded a $1.7 million grant from the National
Institute of Allergy And Infectious Diseases (NIAID) for a period of 1.5
years. The goal of this program is to quickly and reliably advance the
construction of directed mutant gene libraries widely considered
important technology tools for synthetic biology.Verdezyne will apply their proprietary computational and bioinformatics
programs to create highly diverse gene libraries to further enhance
metabolic engineering tools. This enhanced capability will be directly
useful to life science researchers, and serve as a platform
for protein and metabolic engineering.“This grant will fund research to progress the role of bioinformatics in
synthetic biology,” said Stephen Picataggio, Ph.D., Chief Scientific
Officer, Verdezyne. “By advancing this technology, we will be able to
utilize the computational tools for improved protein expression and
function for our internal biofuel and biobased chemical programs.”The project described was supported by STTR program with Award Number
2R42A1066758 from the National Institute of Allergy And Infectious
Diseases. The content is solely the responsibility of the authors and
does not necessarily represent the official views of the National
Institute of Allergy And Infectious Diseases or the National Institutes
of Health.About Verdezyne
Founded in 2005, Verdezyne, formerly known as CODA Genomics, is a
privately-held company that integrates its proprietary core technologies
to direct the evolution of novel metabolic pathways for cost effective
commercial production of biofuels and platform chemicals. Investors in
Verdezyne include OVP Venture Partners, Monitor Ventures, Tech Coast
Angels and Life Science Angels. For more information on Verdezyne, visit www.verdezyne.com.…
